Publish Ahead of Print

Original Article

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
Irena Tan, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, Jeffrey M. Clarke
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer
Takefumi Komiya, Regan M. Memmott, Gideon M. Blumenthal, Wendy Bernstein, Marc S. Ballas, Roopa De Chowdhury, Guinevere Chun, Cody J. Peer, William D. Figg, David J. Liewehr, Seth M. Steinberg, Giuseppe Giaccone, Eva Szabo, Shigeru Kawabata, Junji Tsurutani, Arun Rajan, Phillip A. Dennis

Editorial Commentary

Osimertinib in first line setting: for Asian patients
Keisuke Onoi, Yoshiko Kaneko, Junji Uchino
Measuring tumor mutation burden in cell-free DNA: advantages and limits
Alfredo Addeo, Glen J. Weiss
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)
Greg Durm, Nasser Hanna
Sex disparities in lung cancer incidence: validation of a long-observed trend
Jessica A. Hellyer, Manali I. Patel
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?
Francesco Passiglia, Paolo Bironzo, Giorgio V. Scagliotti
Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
Maria A. Velez, Timothy F. Burns
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Rui Li, Steven M. Dubinett
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
Paul Hofman
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M. Pacheco
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J. Walsh, Ross A. Soo
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, Giulio Metro
Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
Jyoti Malhotra, Salma K. Jabbour, Sharon Pine
Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more
Angel Moran, Megan E. Daly
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Laura Le, Ritchell van Dams, Percy Lee
Improving outcomes for brain metastases in EGFR mutated NSCLC
Jennifer W. Carlisle, Suresh S. Ramalingam
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Andrew J. Piper, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery
Tamar B. Nobel, Prasad S. Adusumilli, Daniela Molena

Study Protocol

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts, on behalf of the DENIM team